Description
The National Heart, Lung, and Blood Institute (NHLBI) is seeking a second Objective Biotechnology “Autoinjector” – a computer‑vision‑guided automated microinjection robot – to expand Drosophila embryo‑injection capacity for transgenic research. The system must match the existing government‑owned instrument in software, consumables, and workflow, enabling parallel operation and increased throughput without additional training or validation effort. This is a single‑source, non‑competitive solicitation under FAR Part 13.
• Purpose: Acquire a second automated microinjection robot for the Rusan Laboratory’s Drosophila work.
• Required capabilities: computer‑vision embryo detection, automated targeting, multi‑axis positioning, injection through intact chorion, identical interface to existing system.
• Quantity: One unit (objective biotechnology autoinjector).
• Delivery: By 09/04/2026 (closing response date) with award expected 09/28/2026; performance period approx. 1 year.
• Funding/Price: Not disclosed; price to be provided in offer (unit price, list price, shipping, discounts).
• Small‑business set‑aside: None – single‑source, brand‑name award.
• Evaluation: Primarily technical fit and price; offerors must be SAM‑registered.